Liqui-Tablet: the innovative oral dosage form using the newly developed Liqui-Mass technology by Lam, Matthew et al.
Liqui­Tablet: the innovative oral dosage form using the newly 
developed Liqui­Mass technology
Article  (Published Version)
http://sro.sussex.ac.uk
Lam, Matthew, Asare-Addo, Kofi and Nokhodchi, Ali (2021) Liqui-Tablet: the innovative oral 
dosage form using the newly developed Liqui-Mass technology. AAPS PharmSciTech, 22 (3). 
a85 1-11. ISSN 1530-9932 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/101625/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
AAPS PharmSciTech (2021) 22: 85
Research Article
Liqui-Tablet: the Innovative Oral Dosage Form Using the Newly Developed
Liqui-Mass Technology
Matthew Lam,1,3 Kofi Asare-Addo,2 and Ali Nokhodchi1,3
Received 26 November 2020; accepted 24 January 2021
Abstract. In this study, an attempt was made to produce Liqui-Tablets for the first time.
This was carried out through the compaction of naproxen Liqui-Pellets. The incentive to
convert the novel Liqui-Pellet into Liqui-Tablet was due to the array of inherent advantages
of the popular and preferred tablet dosage form. The study showed that naproxen Liqui-
Tablet could be successfully produced and the rapid drug release rate (100% drug release ~
20 min) could be achieved under pH 1.2, where naproxen is insoluble. It was observed that
the different pH of the dissolution medium affected the trend of drug release from
formulations with varying amounts of liquid vehicle. The order of the fastest drug-releasing
formulations was different depending on the pH used. The presence of Neusilin US2 showed
considerable enhancement in the drug release rate as well as improving Liqui-Tablet
robustness and hardness. Furthermore, images from X-ray micro-tomography displayed a
uniform distribution of components in the Liqui-Tablet. The accelerated stability studies
showed acceptable stability in terms of dissolution profile.
KEY WORDS: Liqui-Tablet; Liqui-Pellet technology; extrusion-spheronization; dissolution
enhancement; liquisolid technology.
INTRODUCTION
Liqui-Tablet is a newly developed dosage form, stem-
ming from the novel Liqui-Pellet technology, which is also
known as the Liqui-Mass technology. Liqui-Tablet is
compacted Liqui-Pellet; thus, it is also under the Liqui-Mass
system. Note that in previous studies regarding Liqui-Pellet
technology, the final dosage form is in a form of Liqui-Pellet
filled into a hard-shell capsule (1–5). It is a well-known fact
that a tablet is a more commercially favorable dosage form
than a capsule in terms of cost-effectiveness. The manufactur-
ing of tablet have lower production costs and higher
production rates compared to capsules (6), and costly control
steps to ensure capsule integrity are eliminated (7,8). Other
advantages of tablets over capsules include the lower
tendency of dosage form adhering to the esophagus during
ingestion (9); ability to administer higher dose strength than
capsule (10); a reduced risk of dosage form being tampered
with (6); and an improvement in patient compliance, partic-
ularly for those who prefer not to ingest gelatin capsule (11).
It is also worth mentioning that the issues with gelatin
capsules are not just individual preference but extend to
chemical instability (12), the varying dissolution rate of
capsule due to varying structure and composition of gelatin
(13), and questionable source, particularly from waste leather
which may have been treated with harmful substance (14).
Hence, there is an incentive to explore the feasibility of Liqui-
Tablet.
Since Liqui-Tablet stems from Liqui-Pellet, it is impor-
tant to understand Liqui-Pellet. In brief, Liqui-Pellet is a
combination of concepts from liquisolid technology and
pelletization technology. Such a combination can produce a
commercially feasible product when using Liqui-Mass system
(2), where the active pharmaceutical ingredient (API) is in a
liquid state, which is the key feature for the enhanced
dissolution rate. One of the key purposes of this technology
is to improve the bioavailability of poorly water-soluble drugs
by improving its dissolution rate. This is because the
bioavailability of poorly water-soluble drugs, particularly
biopharmaceutical classification class II (BSC II) drugs, is
limited by the API dissolution rate, which affects the
absorption rate (15). Liqui-Pellet and Liqui-Tablet’s primary
mechanism of improved drug dissolution rate is similar to that
of liquisolid formulation, where an increase in surface area
available for dissolution, increase in the solubility of API, and
improved wettability of drug particles result to enhanced drug
release rate (16,17).
Despite Liqui-Pellet technology having similarity to that
of liquisolid technology, it is fundamentally different in that it
uses Liqui-Mass system as oppose to liquisolid system. This
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can be seen in Fig. 1 along with the difference between Liqui-
Pellet and Liqui-Tablet. However, since Liqui-Pellet technol-
ogy is a new technology and studies about it is still in its
infancy, it may sometimes be mistaken as being the same as
liquisolid technology (18). Currently, Lam et al. (1,2,4), Lam
and Nokhodchi (5), Pezzini et al. (19), and Espíndola et al.
(20) are the only research groups that have started working
on the combination of liquisolid and pelletization technology
to overcome liquisolid disadvantages. However, the group of
Lam et al. (1,2,4) and Lam and Nokhodchi (5) uses Liqui-
Mass system (belonging to the Liqui-Pellet technology) and
the group of Pezzini et al. (19) use liquisolid system
(belonging to the liquisolid technology). So far such com-
bined technology has been applied to naproxen (1,2,4,5),
hydrochlorothiazide (3), ketoprofen (3), ritonavir (20), and
felodipine (19).
In order to appreciate the implication of improving the
dissolution rate of poorly water-soluble drugs, it is worth
pointing out that around 40% of drugs in the market are
poorly soluble in the fluid present in the gastrointestinal tract
(GIT), which is based on BCS, and around 90% of drugs in
development are identified as poorly water-soluble (21). Also,
to appreciate Liqui-Mass technology, it should be pointed out
that Liqui-Pellet is able to overcome the major drawbacks in
liquisolid technology, which is still persisting for more than
two decades. These major drawbacks are poor flow proper-
ties, poor compressibility, and an inability to produce high-
dose drugs of a reasonable size and weight for swallowing
(15,16). Liqui-Mass technology overcomes such drawbacks,
enabling the concept of liquisolid to be carried forward into a
commercially feasible direction.
Since Liqui-Tablet is compacted Liqui-Pellet, it has the
same advantages of Liqui-Pellet and arguably more. This is
because capsule filling can be removed from the manufactur-
ing process. Liqui-Pellet has key advantages in terms of
commercial production and versatile formulation design (3).
The potential for commercial production of Liqui-Pellet and
Liqui-Tablet is apparent because advanced performing pills
can be made using simple approaches where green technol-
ogy is applicable and advanced preparation and machinery
are not required (1,2,4). The production itself is not costly
with minimal disruption to current pharmaceutical
manufacturing facilities and processes as all equipment and
excipients required are commonly found in such facilities (2).
In addition, Liqui-Pellet has some key intrinsic advantages
from pelletization and liquisolid technologies. It has inherent
advantages of pelletization technology/multi-unit pellet form
(MUPF) such as good flow property (22); potential to
combine incompatible drugs or drugs with different release
profiles in same dose unit; flexibility for modification via
coating technology; and the reduced likelihood of side effects
due to fast gastric emptying and reduced risk of dose
dumping as well as being distributed more evenly in the
GIT (7,23,24), which also improves bioavailability and reduce
variability in drug release (25).
Furthermore, Liqui-Mass technology is capable of versa-
tile formulation design, such as the addition of functional
excipients or application of coating technology, while having
the API in a liquid state (3). All of these advantageous
features make it a unique and interesting approach to the
future oral dosage form.
Studies by the authors on naproxen Liqui-Pellet and
hydrochlorothiazide Liqui-Pellet (26), which are both poorly
water-soluble drugs, have demonstrated remarkably fast drug
release rate, ~100% drug release rate in 15 min for both
Liqui-Pellet formulations. The dissolution test results from
these two Liqui-Pellet formulations are more rapid than solid
dispersion, liquisolid compact, and solid self-dispersing mixed
micelle forming system.
Despite the advantages of a pellet-based tablet, compac-
tion of pellets into a tablet is a challenging field of research
(25,27). The compaction process could lead to pellets fusing
into each other, producing a non-disintegrating matrix, which
prevents it from reverting into an individual pellet in the GIT;
hence, the advantages of multi-unit pellet system (MUPS)
would no longer be present (27). Also, the compaction
Fig. 1. Diagram to differentiate liquisolid system, Liqui-Mass system, Liqui-Pellet, and Liqui-Tablet
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process poses a major challenge for film-coated pellets, where
functional coating film is prone to damage and rupture during
compression, resulting in unintended changes of the drug
release profile (10,25,27,28).
In this investigation, for the first time, an attempt will be
made to study the feasibility of compacting Liqui-Pellets into
Liqui-Tablets. The Liqui-Pellets are composed of liquid
medication incorporated into a carrier material. The coating
material is then added along with additional excipients. These
pellets can then be compressed into a pellet-based tablet
dosage form, which is shown in Fig. 2. The key objective is to
see if Liqui-Tablets can also achieve a rapid drug release like
Liqui-Pellet. Fortunately, the Liqui-Pellet that will be studied
are not film-coated; therefore, issues concerning the potential
rupture of film-coating material will not be present; however,




Materials included naproxen (TCI, Japan), Avicel PH
101 (FMC corp., UK), Aerosil 300 (Evonik Industries AG,
Hanau, Germany), Primojel (DFE Pharma, Goch, Germany),
Neusilin US2 (Fuji Chemicals, Japan), sodium bicarbonate,
(Acros, NJ, USA), and Tween 80 (Acros, Netherlands). All
other reagents and solvent were of analytical grades.
Production of Liqui-Tablets
The Liqui-Tablet formulations were prepared via
compacting Liqui-Pellets under a specified compression force
using a manual tablet press machine (Compaction model
MTCM-I, Globe pharma, UK). All formulations were
produced similarly except for the variation in parameters
such as carrier composition, Tween 80 concentration, water
content, and liquid load factor as shown in Table I. The liquid
medication, which is naproxen well mixed in Tween 80, was
blended in a specified carrier material alongside with 32%
w/w NaHCO3 (effervescent agent) and Primojel
(superdisintegrant) (Table I). Tween 80 is chosen because it
was the most suitable liquid vehicle based on previous studies
on Liqui-Pellet (1). The reason why 32% w/w NaHCO3 was
chosen is that the previous study on effervescent Liqui-Pellet
showed that it was the most suitable concentration when
considering dosage form total weight and dissolution perfor-
mance (26). The admixture was mixed for 2 min at a constant
rate of 125 rpm using Caleva Multitab (Caleva Process
Solutions Ltd, UK). Primojel was added intragranularly
because it was observed in previous studies that this led to
better disintegration than extragranular incorporation (2).
Deionized water of specified amounts was gradually added to
achieve a reasonable plastic property for extrusion using
Caleva Multitab, which can mix, extrude, and spheronize.
This admixture was mixed for a further 5 min before
incorporating the Aerosil 300 (coating material). The new
admixture was then further mixed for another 5 min before
extrusion and spheronization at an almost constant rotation at
4000 rpm (decrease to 2000 rpm if agglomeration seems
likely). The duration of spheronization varied depending on
the extrudate’s physical property to avoid agglomeration. The
moist Liqui-Pellets were then placed in an oven under a
constant temperature of 40°C overnight to evaporate excess
water content.
The physical mixture pellet was prepared in a similar
manner described above including 32% w/w NaHCO3, but
without liquid vehicle incorporated. All formulation’s carrier
to coating material ratio was kept constant at 20:1
respectively.
Pre-Compacted Flowability Test
Flow property of pre-compressed Liqui-Tablet formula-
tions was analyzed using well-established methods, which
were also applied to previous studies on Liqui-Mass technol-
Fig. 2. Diagram showing the structure of Liqui-Pellet and how Liqui-Tablet is formed
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ogy (1,2). The methodology used includes standard flow rate
in grams per second, angle of repose, and Carr’s compress-
ibility index (100 taps in 4 min).
Friability Test on All Formulation
Formulation robustness was investigated using a
friabilitor chamber (D-63150, Erweka, Germany). Samples
consisting of 10 Liqui-Tablets of specified formulation were
set to tumble in the friabilitor machine under constant
rotation of 25 rpm for 4 min. The % weight loss of samples
was calculated using the weight of samples before and after
the tumbling.
Tablet Hardness Test
All formulations were subjected to tablet hardness tests
except for formulations F-2 and F-8, which were too soft for
the tablet hardness test. Each formulation was placed in a
tablet hardness tester (TBH 125, Erweka, Germany) where
the diameter and thickness of each tablet were measured. The
tablet hardness tester then measured the amount of force (in
Newton) required to fracture the tablet. This was repeated 5
times for each formulation and the mean was calculated.
Tomography Study
X-ray micro-tomography (XμT) (Nikon XT H 225,
Nikon Corp. Tokyo, Japan) was used to assess the tomogra-
phy of formulation F-5. As formulation F-5 showed the fastest
dissolution rate at pH 7.4, it was selected for tomography
study. The instrument was set up using a tungsten target, with
90 kV accelerating voltage and an 80 μA gun current.
Formulation F-5 was mounted using a double-sided adhesive
tape onto a sample stage. Then, a set of 1583 projections was
collected from the instrumentation after which these images
were reconstructed using CT-Pro, and then examined using a
VG Studio 2.1 software.
In Vitro Drug Release Test
All successful formulations were subjected to a dissolu-
tion test using the USP paddle method (708-DS Dissolution
Apparatus & Cary 60 UV-Vis, Agilent Technologies, USA).
The dissolution tests were carried out in such that 900 mL of
dissolution medium was at a constant temperature of 37.3 ±
0.5°C. The paddle rotation was set to 50 rpm and the
dissolution medium used was either HCl buffer solution at
pH 1.2 or phosphate buffer solution at pH 7.4 to simulate
fluid in the gastrointestinal tract without enzymes. Spectro-
photometric analysis was set to read at wavelength 271 nm at
a time interval of 5 min for an hour then a time interval of
10 min for another hour. It should be pointed out that sink
condition was not maintained for pH 1.2 and this pH was only
used for comparison of various formulations. Under constant
temperature of 35°C, naproxen solubility at pH 1.2 was 27
mg/L (29); hence, 25 mg used in test seemed reasonable.
However, naproxen is very soluble at pH 7.4 (~3347 mg/L
(29); therefore, the sink condition was maintained at this pH.
Table I. Key Formulation Characteristics of the Investigated Liqui-Tablet
Formulation Water content during
extrusion-spheronization
(mL) per 20g of admix-




















o f 2 5 m g











58.06 2.90 400 135.25




58.06 2.90 800 135.25
F-1 5.60 19 1 5.92 Composition
1
62.54 3.15 400 197.20
F-2 3.12 23 1.23 7.69 Composition
1
55.06 2.75 400 197.20
F-3 3.20 19 1 5.92 Composition
2
62.54 3.15 400 197.20
F-4 3.20 23 1.23 5.92 Composition
2
55.06 2.75 400 197.20
F-5 3.20 23 1.23 5.92 Composition
2
55.06 2.75 600 197.20
F-6 3.20 23 1.23 5.92 Composition
2
55.06 2.75 800 197.20
F-7 5.60 19 1 5.92 Composition
1
62.54 3.15 800 197.20
F-8 3.12 23 1.23 7.69 Composition
1
55.06 2.75 800 197.20
Note all formulations contain 25mg of naproxen and 32% w/w NaHCO3, and the carrier to coating material is at a ratio of 20:1
a Carrier composition of 100% Avicel PH101
b Carrier composition of 50% Avicel PH101 & 50% Neusilin US2
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Dissolution profiles were analyzed using mathematical
methods called difference factor (f1) and similarity factor (f2).
Such mathematical methods have been recommended by the
US FDA (Food and drug administration) (30) and imple-
mented by the FDA in various guidance documents (31,32).
Difference factor with a value between 0 and 15 and similarity
factor with a value between 50 and 100 imply the equivalence
of the two dissolution profiles (33).
Accelerated Stability Test
The accelerated stability test was carried out on formu-
lation F-5, which was one of the fastest drug-releasing Liqui-
Tablets in this investigation. The sample was stored at 40°C
with a relative humidity of 75%. The duration of the tests was
3 months, where changes in physical appearance and drug
release profiles were recorded each month for 3 months.
RESULTS AND DISCUSSION
Pre-Compression Flowability Studies on All Formulation
According to flowability results in Table II, there is no
issue in terms of flow properties for all formulations.
Inference from the angle of repose method shows that all
formulations achieve excellent flow properties. There is more
variation from the CI; however, there is no issue in flowability
as the results ranged from excellent to good flowability. Such
results are typical in Liqui-Pellet formulations and further
support the claim that this technology has overcome the issue
of poor flowability that was prevalent in classical liquisolid
technology.
Studies on Liqui-Tablet Robustness
The compaction of Liqui-Pellets into Liqui-Tablet was
successful; however, not all formulations passed the friability
test, which suggests that some formulations are not robust
enough (Table III). Physical mixture 1 and formulations F-1,
F-2, F-7, and F-8 all fractured, thus, failing the friability test.
Interestingly, all of those failed formulations did not contain
Neusilin US2, and all of the formulations that passed the
friability test contained Neusilin US2. Hence, it seems that
the carrier composition is an important factor to consider in
Liqui-Tablet production. It is speculated that the extremely
large specific surface area of Neusilin US2 (an amorphous
form of magnesium aluminometasilicate), which is 300 m2/g
(34), may have contributed to the sufficient bonding strength
upon compaction of the Liqui-Pellets; hence, Liqui-Tablets
containing Neusilin US2 were robust enough to pass the
friability test. In addition, tablet hardness test results
(Table IV) showed that formulations containing Neusilin
US2 have increased hardness.
Both physical mixtures 1 and 2 have the same composi-
tion; the only difference is that different compression forces
were applied, 400 PSI and 800 PSI respectively. Physical
mixture tablet 1, which was made using lower compression
force than physical mixture tablet 2, failed the friability test,
and physical mixture tablet 2 passed. This indicates that
compaction force influences the physical property of the
physical mixture tablet and that higher compaction force
results in a more robust tablet.
All Liqui-Tablets which contain Neusilin US2 passed the
friability test despite the differences in liquid vehicle










Physical mixture 1 8.75 ± 0.19 24.39 ± 0.56 13.32 ± 0.00 Excellent Good
Physical mixture 2 8.75 ± 0.19 24.39 ± 0.56 13.32 ± 0.00 Excellent Good
F-1 8.10 ± 0.17 26.71 ± 0.20 10.23 ± 0.00 Excellent Excellent to good
F-2 7.81 ± 0.28 28.92 ± 0.49 10.33 ± 1.14 Excellent Excellent to good
F-3 7.86 ± 0.19 28.58 ± 1.00 11.17 ± 0.00 Excellent Good
F-4 8.37 ± 0.11 26.83 ± 0.79 10.23 ± 0.00 Excellent Excellent to good
F-5 8.37 ± 0.11 26.83 ± 0.79 10.23 ± 0.00 Excellent Excellent to good
F-6 8.37 ± 0.11 26.83 ± 0.79 10.23 ± 0.00 Excellent Excellent to good
F-7 8.10 ± 0.17 26.71 ± 0.20 10.23 ± 0.00 Excellent Excellent to good
F-8 7.81 ± 0.28 28.92 ± 0.49 10.33 ± 1.14 Excellent Excellent to good
a For the composition of each formulation, refer to Table I
b SD, standard deviation from the mean
Table III. Friability Test Results of All Formulations
Formulationa % weight loss Fractured (yes/no) Pass/fail
Physical mixture 1 NAb Yes Fail
Physical mixture 2 0.15 No Pass
F-1 NAb Yes Fail
F-2 NAb Yes Fail
F-3 0.00 No Pass
F-4 0.00 No Pass
F-5 0.00 No Pass
F-6 0.00 No Pass
F-7 NAb Yes Fail
F-8 NAb Yes Fail
a For the composition of each formulation, refer to Table I
b Not applicable
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concentration and compression force. Thus, Neusilin US2
seems to be the single most important factor in Liqui-Tablet
that influences the dosage form robustness. These Liqui-
Tablet formulations have 0% weight loss after being sub-
jected to the friabilitor, which is due to the plastic property of
the formulations. This plastic property makes the tablet
resistant to friability.
Although some formulations failed the friability test due
to fracturing of the Liqui-Tablet, it should be noted that there
are simple approaches to overcome this issue such as
incorporating binding excipient, manipulating the pre-
compressed Liqui-Tablet physical properties, or incorporating
a mixture of excipient-based pellet with the Liqui-Pellet. Such
modifications will be carried forward in future investigation.
Tablet Hardness Test
The tablet hardness test results (Table IV) show that the
compression force has major influences on the hardness of the
physical mixture tablet, but interestingly have hardly any
influences on Liqui-Tablet formulations. Physical mixtures 1
and 2 have the same composition, but physical mixture 2 was
compressed with double the amount of force compared to
physical mixture 1 (800 PSI and 400 PSI respectively), which
results to physical mixture 2 having around twice the hardness
of the physical mixture 1 compacts (56.8 N and 102.6 N
respectively). However, in the case of Liqui-Tablets, the
compression force seems to have hardly any effect on its
hardness. This can be seen in formulations F-1 and F-7, where
both formulations have the same composition (Table I), but
F-7 was compressed with twice as much force than F-1 (800
PSI and 400 PSI respectively). Despite the difference in
compression force, both F-1 and F-7 hardness are not very
much different (85.2 N and 73.6 N respectively). A similar
observation was made for formulations F-4, F-5, and F-6
where their composition is the same but the compression
force differs (400 PSI, 600 PSI, and 800 PSI respectively), but
their tablet hardness are similar (54.6 N, 60.6 N, and 52.4 N
respectively).
It is observed that the amount of liquid vehicle in the
Liqui-Tablet formulation has major influences on Liqui-
Tablet hardness. By increasing liquid vehicle concentration,
the hardness of Liqui-Tablet is reduced. This is shown in
formulations F-3 and F-4 where both compositions are the
same except for the amount of liquid vehicle (concentration
of Tween 80 of 19% w/w and 23% w/w respectively). With the
higher concentration of Tween 80 in F-4 in comparison to F-3,
the tablet hardness is reduced considerably (54.6 N and
90.4 N respectively). The influences of the liquid vehicle are
also shown in F-1 and F-2, where both formulations are
identical except that F-2 has a higher concentration of Tween
80 than F-1, which results to F-2 being too soft for the tablet
hardness test. A similar observation is made for F-7 and F-8,
where F-8 having a higher amount of Tween 80 is too soft for
tablet hardness test to be carried out. Hence, liquid vehicle
concentration is one of the major parameters that determine
Liqui-Tablet hardness.
Another observed parameter that has major influences
on the Liqui-Tablet hardness is the carrier composition.
Formulations containing Neusilin US2 increase Liqui-Tablet
hardness. This is shown in F2 and F4 where both have the
same high concentration of Tween 80 (23% w/w) and
compressed at the same force (400 PSI); however, only F-2,
which is absent of Neusilin US2, is too soft for hardness test
to be applied. The same observation is made in F-8 and F-6,
where F-8, which does not contain Neusilin US2, is too soft to
be tested by the tablet hardness tester.
Overall, liquid vehicle concentration and carrier compo-
sition are important factors to consider in terms of Liqui-
Tablet hardness. As for the compression force, it does not
seem to have any observable effect on Liqui-Tablet hardness.
Tomography
X-ray tomography of F-5 is shown in Fig. 3. The black
spaces are the porosity within the compact. The continuous
black lines show the individual pellets that are compressed to
make the compact. The different colorations in these figures
are assigned to the different components that made the F-5.
By looking at the formulation table and the amount/content
of each excipient used, it is possible to determine which color
belongs to which excipient. Generally, it can be said the figure
shows the components in the Liqui-Tablet are distributed
uniformly.
In Vitro Dissolution Test
The dissolution test results of all formulations under
acidic conditions (pH 1.2), which is used to mimic the
stomach condition, are shown in Fig. 4. The results show a
Table IV. Tablet Hardness Test Results of All Formulations
Formulationa Mean thickness ± SDb (mm) Mean diameter ± SDb (mm) Mean hardness ± SDb (N)
Physical mixture 1 5.98 ± 0.05 5.23 ± 0.02 56.80 ± 10.94
Physical mixture 2 5.60 ± 0.01 5.25 ± 0.01 102.60 ± 13.03
F-1 7.92 ± 0.05 5.25 ± 0.01 85.20 ± 8.11
F-3 7.55 ± 0.02 5.26 ± 0.01 90.40 ± 2.70
F-4 7.66 ± 0.02 5.26 ± 0.00 54.60 ± 3.13
F-5 7.61 ± 0.03 5.25 ± 0.00 60.60 ± 5.27
F-6 7.60 ± 0.02 5.27 ± 0.01 52.40 ± 2.51
F-7 7.87 ± 0.02 5.26 ± 0.01 73.60 ± 5.59
a For the composition of each formulation, refer to Table I
b SD, standard deviation from the mean
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trend that increasing liquid vehicle concentration results to
increase in drug release rate. This is shown when comparing
similar formulations with different liquid vehicle concentra-
tion such as F-1 (Tween 80 19% w/w) and F-2 (Tween 80 23%
w/w), where F-2 have ~17% more drug release after 2 h than
F-1 (f1= 23.61 and f2= 38.89). This is also observed in other
formulations such as F-7 (Tween 80 19% w/w) and F-8
(Tween 80 23% w/w), where F-8 have ~17% more drug
release after 2 h than F-7 (f1= 24.55 and f2= 38.03); and F-3
(Tween 80 19% w/w) and F-4 (Tween 80 23% w/w), where F-
4 have ~4% more drug release after 2 h than F-3 (f1= 8.71 and
f2= 47.52). Such observation is in agreement with the authors’
previous studies on the crucial effect of co-solvent in Liqui-
Pellet (4), which also contains solid-state analysis on the
naproxen Liqui-Pellet. In general, XRPD and DSC data
showed naproxen Liqui-Pellets have a reduced crystallinity in
comparison to the physical mixture pellet.
It is expected that the increase in non-volatile co-solvent
increases the proportion of API in the molecular state in the
liquid vehicle, which increases the diffusion of API from
Liqui-Pellets to the dissolution medium (17). Previous
saturation solubility study (under constant agitation at 37°C
for 72 h) showed that naproxen solubility in Tween 80 was
21.85 mg/mL, which is considered sparingly soluble (4).
Therefore, it would make sense that more Tween 80 would
result in more naproxen being solubilized. Naproxen is only
partially dissolved in Tween 80, which was determined using
the mentioned saturated solubility data and Tween 80 density
1.5 mm
ba
Fig. 3. X-ray micro-tomography of the sagittal and diametric images of compacted F-5
Liqui-Tablet formulation a side of the tablet b top of the tablet. Note: This tomography
technique is based on the differential absorbance of X-rays between materials of differing
electron density. The color code is therefore from the density histogram. The green
coloration represents the bulk of the material from the formulation which for F5 is the
carrier composition of 50% Avicel PH101 & 50% Neusilin US2. The pink coloration
represents the naproxen content with the blue color surrounding it representing the liquid
vehicle. The black coloration within the Liqui-Tablet representing the pore spaces as well
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Fig. 4. Dissolution profiles of all formulations at pH 1.2
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(1.06 g/cm3). It is estimated that the formulation containing
19% Tween 80 has 25 mg of naproxen in ~0.035 mL Tween
80, and 25 mg of naproxen in ~0.043 mL for the formulation
with 23% Tween 80. Furthermore, since Tween 80 reduces
surface tension/cohesive force, the higher the amount of
Tween 80 the greater the extent of disintegration, thus,
further enhancing the drug release. A similar finding in terms
of Tween 80 improving propensity of the disintegration of
MCC-based pellet was observed by Chamsai and
Sriamornsak (35).
When comparing formulations with identical composi-
tion but under different compression forces, there is no
observable effect on the drug release rate. This can be seen
when comparing F-1 and F-2/F-7 and F-8/F-4/F-5 and F-6.
Unlike a compressed powdered tablet, where the compres-
sion force can significantly influence the propensity of
disintegration and consequently drug release rate, the Liqui-
Tablet reverts back to pellet form under a minute; hence,
there is less variation in disintegration and drug dissolution
rate for Liqui-Tablet made under different compression force.
Formulations with Neusilin US2 have significantly faster
drug release rate than formulations absent of Neusilin US2.
This is shown when comparing formulation F-1 and F-3,
where both have the same liquid vehicle concentration and
compression force, but F-3 has a significantly faster drug
release rate due to the presence of Neusilin US2. Formulation
F-3 reached 100% drug release after ~45 min, whereas F-1
only reached ~71% drug release after 2 h (f1= 41.17 and f2=
21.51). A similar observation is made in formulations F-2 and
F-4, where F-4 drug release rate is considerably faster due to
the presence of Neusilin US2. Formulation F-4 start
plateauing at 100% drug release at around 25 min, whereas
F-2 only reached 86% drug release after 2 h (f1= 27.18 and f2=
28.33). It is speculated that the increase in dissolution rate
could be due to a possible naproxen complexation with
Neusilin. In a study by Gupta et al. (36), it was reported that
amorphization of naproxen (including other acidic API) was
formed during ball milling with Neusilin, which was sup-
ported through X-ray powder diffraction and differential
scanning calorimetry. It was mentioned that the drug
hydrogen bonds onto the extensive surface of Neusilin,
reducing the crystalline phase of the drug. The complexation
of the amorphous state of naproxen was due to an acid-base
reaction between carboxyl moiety of naproxen and the
Neusilin silanol or due to ion-dipole interactions between
metal ions in Neusilin and the drug. Due to the higher energy
of the amorphous phase, the drug solubility and dissolution
rate increased. In the case of Liqui-Tablet, the naproxen was
not milled but the stress induced by liquid vehicle and
extrusion process likely reduces the crystalline phase. The
naproxen that can potentially recrystallize out of the liquid
medication or those not fully solubilized in Tween 80 may
complex with Neusilin US2 to form a stable amorphous state,
therefore enhancing dissolution rate. However, more investi-
gation is required to confirm this.
On comparing the dissolution profile of formulation F-6,
which displayed one of the fastest drug release rate in this
study, with the fastest drug-releasing naproxen Liqui-Pellet
from the author’s previous work (37), there is no observable
difference in the drug release profile at pH 1.2, both plateau
to 100% after 20 min. The effervescent agent in the Liqui-
Tablet interacts with the acidic dissolution medium, which
produces CO2 gas, promoting disintegration and a very fast
transition from tablet to pellet form. However, in an alkaline
environment (pH 7.4), the Liqui-Tablet drug release is slower
than the Liqui-Pellet in a capsule. This is because the
effervescent agent is not triggered at this alkaline pH.
The dissolution test results in alkaline condition (pH 7.4)
mimic the small intestine pH condition where naproxen is
soluble (Fig. 5). It is surprising to see that the physical
mixture Tablets I and II had a faster drug release rate than
the Liqui-Tablet formulations. It is postulated that since the
API is soluble at this alkaline pH, the rate-limiting step for
drug release is the disintegration rate and surface area
available for drug release. If that is the case, then perhaps
the liquid vehicle in Liqui-Tablet is reducing the propensity of
disintegration as it could be acting as a binding material,
hence, displaying slower drug release. Such postulation comes
from data in Table IV, where it can be seen that under
compression force 400 PSI, the formulation with Tween 80
(F-1 = 85.2 N and F-2 = 90.4 N) is harder than the physical
mixture (56.8N). This postulated binding action on drug
release is not observed at pH 1.2 because the effervescent
agent is triggered in an acidic environment. The results from
Fig. 5 also show that compression force does not have a major
effect on Liqui-Tablet drug release rate as seen in formula-
tions F-4, F-5, and F-6, where all of these formulations’
composition are the same but the compression force applied
to them are different (400 PSI, 600 PSI, and 800 PSI
respectively).
Overall, varying compaction force does not seem to have
any influences on Liqui-Tablet drug release rate. Naproxen
Liqui-Tablet drug release at acidic pH is considered very fast
(F-6 starting to plateau at 20 min) and more rapid than
naproxen solid dispersion (38) and naproxen liquisolid
compact (39).
The concentration of liquid vehicle and the presence of
Neusilin US2 have major influences on the drug release rate
at acidic pH. As expected, the increase in liquid vehicle
concentration improves the enhancement of drug release at
pH 1.2. It is noteworthy to point out that the formulation with
the highest amount of Tween 80 (23% w/w or 45.35mg per
dose unit) is below Tween 80’s maximum potency per unit
dose for oral tablet according to US FDA, which somewhat
reflects the safety potential for commercial manufacturing of
such dosage forms.
It is interesting to observe that at pH 7.4, the liquid
vehicle in Liqui-Tablet could be responsible for slowing down
the drug release rate possibly due to binding action, which
reduces the propensity for disintegration. The presence of
Neusilin US2, which is part of the carrier material, improves
the drug release rate considerably. Not only does Neusilin
US2 improves drug release rate but it also improves the
robustness and hardness of Liqui-Tablet (Tables III and IV),
making it a valuable excipient in this technology. Future
studies will include investigating different excipients that may
improve Liqui-Tablet quality and drug release performance.
Accelerated Stability Studies
The drug release rate of formulation F-5 (Fig. 6) was
investigated under stress conditions for the accelerated
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stability test over 3 months. In comparing F-5 drug dissolution
profile at month 0 and a month afterwards (month 1), there is
a difference in the dissolution profile (f1 = 22.52 and f2 =
42.61), indicating some degree of decrease in drug release.
This difference in dissolution profile may be due to changes in
the formulation over storage time such as pellet becoming
harder over time. The degradation becomes less apparent
after the first month where F-5 drug dissolution profile in
month 1 and month 2 shows f1 = 3.03 and f2 = 80.61. A similar
observation is made between month 2 and month 3 where f1 =
5.01 and f2 = 72.46.
CONCLUSION
The Liqui-Tablet formulation was successfully
manufactured for the first time using naproxen as the drug
model. In comparison to the rapid drug release of naproxen
Liqui-Pellet from previous studies, it can be concluded that
the rapid drug release is maintained in Liqui-Tablet dosage
form at acidic pH. Nonetheless, when comparing the dissolu-
tion profile of the best naproxen Liqui-Tablet with other
studies concerning naproxen solid dispersion and liquisolid
compact, the drug release rate of Liqui-Tablet is more rapid.
It is interesting how the liquid vehicle in naproxen Liqui-
Tablet under pH 7.4 actually slows down the drug release
rate. This is possibly due to liquid vehicle binding effect
within the Liqui-Tablet, which reduces the propensity for
disintegration. The disintegration step seems to be the rate-
determining step at this pH as API solubility is no longer an
issue. Compression force show little influence on Liqui-Tablet
hardness; however, liquid vehicle concentration has a consid-
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Fig. 6. Stability test of formulation F-5 represented through dissolution profile taken each
month over the period of 3 months under pH 1.2
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The studies also confirm that compaction force during
tableting has no observable effect on the Liqui-Tablet drug
release rate. The presence of Neusilin US2 in Liqui-Tablet
formulations has shown to be an important factor to achieve
ideal Liqui-Tablet physical properties such as robustness and
hardness, as well as allowing faster drug release rate to be
achieved. The improved drug release rate may be due to
amorphous naproxen and Neusilin US2 complex, but require
further investigation to confirm this. Furthermore, acceler-
ated stability studies have shown acceptable stability.
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